1. Japan Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Shimadzu Corporation

Shimadzu Corporation

23.80
EUR
0.00
(0.00%)
Nov 06Next Earn
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
1,042.7
1,067.16
1,160.68
1,161.61
1,277.82
1,328.09
1,308.51
1,335.6
1,453.16
1,636.56
1,736.95
1,839.85
1,940.64
- -
Basic EPS, GAAP
32.97
62.55
81.05
89.79
101.26
110.41
107.84
122.52
160.49
176.63
193.54
183.55
209.38
- -
Free Cash Flow per Basic Share
-62.17
87.34
71.27
63.07
99.24
29.43
80.26
171.37
180.67
106.78
49.63
125.95
137.53
- -
Dividend per Share
9
9.5
16.98
18.98
20.99
26.01
30.01
30
39
50.04
55.96
62.29
66.98
- -
Book Value per Share
616.5
711.37
745.12
818.55
908.76
977.34
1,027.86
1,138.66
1,293.6
1,437.19
1,670.49
1,723.87
1,955.96
- -
Tangible Book Value per Share
592.9
686.63
719.49
790.08
877.41
940.57
989.02
1,099.24
1,255.75
1,379.62
1,609.37
1,641.69
1,873.29
- -
Basic Weighted Avg Shares
295
295
295
295
295
295
295
295
295
295
295
293
289
289
Sales/Revenue/Turnover
307,532
314,702
342,236
342,479
376,530
391,213
385,443
393,499
428,175
482,240
511,895
539,047
560,728
- -
Operating Margin (%)
7.81
8.64
10.43
10.83
11.37
11.37
10.86
12.64
14.9
14.15
14.21
13.3
13.14
- -
Depreciation Expense
8,050
7,951
9,425
9,546
10,591
11,506
13,256
15,536
16,205
17,524
18,551
19,895
20,381
- -
Net Income, GAAP
9,724
18,445
23,899
26,473
29,838
32,523
31,766
36,097
47,289
52,048
57,037
53,776
60,499
- -
Effective Tax Rate (%)
28.62
30.91
29.55
26.53
28.38
27.02
26.33
27.54
28.29
26.52
25.89
25.03
25.73
- -
Profit Margin (%)
3.16
5.86
6.98
7.73
7.92
8.31
8.24
9.17
11.04
10.79
11.14
9.98
10.79
- -
Working Capital
102,679
134,182
144,079
158,933
162,258
157,628
170,166
191,350
235,620
259,122
308,425
303,169
347,480
- -
LT Debt
2,493
17,628
17,545
17,406
17,487
2,575
3,552
5,226
6,627
6,631
6,884
6,844
6,450
- -
Total Equity
181,993
210,015
219,969
241,627
268,059
287,940
302,773
335,502
381,162
423,498
492,333
498,064
565,164
- -
Return on Invested Capital (%)
7.66
7.79
10.29
10.59
10.86
10.64
9.82
10.78
12.09
11.81
11.26
10.43
9.87
- -
Return on Capital (%)
4.48
7.79
10.01
10.51
10.8
10.87
10.28
11.04
12.84
12.63
12.19
10.65
11.19
- -
Return on Common Equity (%)
5.48
9.42
11.13
11.48
11.72
11.71
10.76
11.31
13.2
12.94
12.46
10.86
11.38
- -

Capital Structure

JPY

•

in mil. unless spec.
Sep'26
Mar'26
Jun'27
ST Debt
4,714
4,033
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
6,677
6,450
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
289
289
289
Market Capitalization
- -
- -
- -

Working Capital

JPY

•

in mil. unless spec.
Sep'26
Mar'26
Jun'27
Total Current Assets
450,919
497,728
- -
Cash, Cash Equivalents & STI
152,230
167,316
- -
Accounts Receivable, Net
131,152
156,326
- -
Inventories
151,372
152,098
- -
Total Current Liabilities
135,478
150,248
- -
Payables & Accruals
- -
- -
- -
ST Debt
4,714
4,033
- -
Deferred Revenue
- -
- -
- -

Growth Rates

JPY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
9.98%
11.12%
13.47%
Free Cash Flow
33.27%
14.2%
7.69%
Net Income, GAAP
10.12%
11.49%
12.5%
Sales/Revenue/Turnover
5.14%
7.38%
4.02%
Total Cash Common Dividend
- -
17.37%
6.05%

Quarterly Revenue

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
539,047
2026
- -
- -
- -
- -
560,728
2027
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
183.55
2026
- -
- -
- -
- -
209.38
2027
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
62.29
2026
- -
- -
- -
- -
66.98
2027
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Yasunori Yamamoto
Full Time Employees
14,649
Sector
Health technology
Industry
Medical specialties
Address
1 Nishinokyo Kuwabara-cho Kyoto KY Japan 604-8511
IPO Date
May 16, 1949
Website
shimadzu.co.jp
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Shimadzu Corporation manufactures and sells analytical and measuring instruments, medical systems, aircraft equipment, vacuum and industrial machinery, hydraulic equipment, and optical devices. The company offers a broad range of analytical products including chromatographs such as high-performance liquid chromatography (HPLC), ultra-high-performance liquid chromatography (UHPLC), gas chromatography (GC), supercritical fluid chromatography (SFC), and multidimensional chromatography systems; mass spectrometers including liquid chromatograph mass spectrometers (LCMS) like the Nexera CL and LCMS-8065XE; spectroscopy instruments such as Fourier transform infrared (FTIR) spectrometers, ultraviolet-visible (UV-VIS) spectrophotometers, fluorescence spectrometers, and energy-dispersive X-ray fluorescence (XRF) spectrometers like the ALTRACE; balances including analytical balances AP W-AD ex and AP W ex; scanning probe microscopes like the SPM-9700HT Plus; microchip electrophoresis systems such as MultiNA II; high-speed video cameras including HyperVision HPV-X3; and software solutions like LabSolutions Detect for AI impurity detection and MicrobialTrack for microbial identification. In medical systems, Shimadzu provides diagnostic imaging equipment encompassing X-ray systems including mobile X-ray systems like MobileDaRt Evolution MX9, computed tomography (CT) systems such as inspeXio 7000, positron emission tomography (PET) systems like PositView, and R/F systems with Smart FOV software; Vacuum and industrial machinery includes semiconductor manufacturing equipment, testing systems like Autograph AGS-V precision universal testing machines, particle analysis systems for microplastics, and gas analyzers like FluxEdge GC and TOC-1000e; aircraft equipment covers components for commercial aircraft; hydraulic equipment includes systems developed jointly with partners; and optical devices support diverse applications. Shimadzu operates globally with subsidiaries and sales offices in the United States, Europe, China, India, South Korea, Southeast Asia, Australia, and other regions, serving industries such as pharmaceuticals, biotechnology, food and agriculture, environmental testing, semiconductors, chemicals, energy, and healthcare; the company was founded in 1875 and is headquartered in Kyoto, Japan. Recent developments include a strategic partnership with Japan Activation Capital signed in November 2025 to enhance corporate value; a business alliance with Sumitomo Precision Products announced in November 2025 for hydraulic equipment development aiming for 2027 product launches; exclusive marketing partnership with Sepragen Corporation from November 2024 for bioprocess chromatography products in Japan, South Korea, and Southeast Asia; a comprehensive collaborative agreement with Osaka Metropolitan University in September 2025 for all-solid-state batteries and infectious diseases research; integration of two European group companies in April 2025 to strengthen analytical reagents business; formation of Shimadzu Aerotech Manufacturing Inc. in April 2025 to meet aircraft demand; investments by its CVC fund Shimadzu Future Innovation Fund in 2025 including Persist AI, SUN METALON Inc., RLWRLD Inc., and Basetwo AI; launch of new facilities such as the Environmental Health Innovation Center in Hangzhou China in June 2025, Shimadzu Kobe Innovation Lab in May 2025, and a new plant in India planned for 2027 operation; and product releases including the i-Series integrated HPLC in September 2025, LCMS-8065XE in August 2025, and multiple chromatography and analysis systems throughout 2025.

Company News

Company News APIChatGPT

  • defenseworld.net

    Hexagon (OTCMKTS:HXGBY) vs. Shimadzu (OTCMKTS:SHMZF) Critical Review